Price
CHART BY
Frequently asked questions
What is Dynavax Techs's market capitalization?
The market capitalization of Dynavax Techs is $1.80B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Dynavax Techs?
Dynavax Techs's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.382. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Dynavax Techs's stock?
Currently, 3 analysts cover Dynavax Techs's stock, with a consensus target price of $22.00. Analyst ratings provide insights into the stock's expected performance.
What is Dynavax Techs's revenue over the trailing twelve months?
Over the trailing twelve months, Dynavax Techs reported a revenue of $330.51M.
What is the EBITDA for Dynavax Techs?
Dynavax Techs's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $18.68M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Dynavax Techs?
Dynavax Techs has a free cash flow of $80.54M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Dynavax Techs have, and what sector and industry does it belong to?
Dynavax Techs employs approximately 405 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Dynavax Techs's shares?
The free float of Dynavax Techs is 116.65M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.80B
- EPS (TTM)
- -$0.382
- Free Float
- 116.65M
- Revenue (TTM)
- $330.51M
- EBITDA (TTM)
- $18.68M
- Free Cashflow (TTM)
- $80.54M
Pricing
- 1D span
- $15.21$15.41
- 52W span
- $9.205$15.49
Analyst Ratings
The price target is $22.00 and the stock is covered by 3 analysts.
Buy
2
Hold
1
Sell
0
Information
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
- Employees
- 405
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- DVAX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet